The major indications for treatment of paravalvular leaks include severe symptoms with valve regurgitation and persistent, severe hemolysis requiring multiple periodic blood transfusions. The current gold standard for treatment of paravalvular leaks is surgery with either replacement or resuturing of the original prosthesis. Reoperation is associated with higher mortality and morbidity than the initial operation, with reported mortality as high as 13%, 15% and 37% following first, second and third procedures, respectively.4 The operative mortality after paravalvular leak surgery is around 7%, and the perioperative stroke rate of 5% with a 10-year Kaplan.Meier survival of 30%. In elderly patients with comorbidities, and in patients with multiple prior chest surgeries, however, the risks of reoperation frequently prohibit surgery. In these patients, percutaneous closure offers an attractive alternative for the treatment of paravalvular leaks, as it is considerably less invasive than surgery and might be associated with fewer risks to the patient.5–7

" /> The major indications for treatment of paravalvular leaks include severe symptoms with valve regurgitation and persistent, severe hemolysis requiring multiple periodic blood transfusions. The current gold standard for treatment of paravalvular leaks is surgery with either replacement or resuturing of the original prosthesis. Reoperation is associated with higher mortality and morbidity than the initial operation, with reported mortality as high as 13%, 15% and 37% following first, second and third procedures, respectively.4 The operative mortality after paravalvular leak surgery is around 7%, and the perioperative stroke rate of 5% with a 10-year Kaplan.Meier survival of 30%. In elderly patients with comorbidities, and in patients with multiple prior chest surgeries, however, the risks of reoperation frequently prohibit surgery. In these patients, percutaneous closure offers an attractive alternative for the treatment of paravalvular leaks, as it is considerably less invasive than surgery and might be associated with fewer risks to the patient.5–7

"> Author Profile – Methodist Journal
Methodist Journal

FEATURED GUEST EDITOR

ISSUE INTRO

The Burgeoning Field of Cardio-Oncology

See More
RECOGNITIONS

Barry H. Trachtenberg Leads Issue on Cardio-Oncology

See More

REVIEW ARTICLES See More

Heart Failure in Relation to Anthracyclines and Other Chemotherapies

Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies

The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics

Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity

Cardiovascular Toxicities of Radiation Therapy

Electrophysiologic Complications in Cancer Patients

Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment?

Future Directions in Cardio-Oncology

CASE REPORTS See More

A Rare Case of Pancreatitis-Induced Thrombosis of the Aorta and Superior Mesenteric Artery

Anomalous Origin of the Right Coronary Artery from the Left Main Coronary Artery in the Setting of Critical Bicuspid Aortic Valve Stenosis

Simultaneous Transfemoral Mitral and Tricuspid Valve in Ring Implantation: First Case Report with Edwards Sapien 3 Valve

Uneventful Follow-Up 2 Years after Endovascular Treatment of a High Flow Iatrogenic Aortocaval Fistula Causing Pulmonary Hypertension and Right Heart Failure

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

Do Not Pass Flow: Microvascular Obstruction on Cardiac Magnetic Resonance After Reinfarction Following Primary Percutaneous Coronary Intervention

CLINICAL PERSPECTIVES See More

EXCERPTA

Cardio-Oncology, Then and Now: An Interview with Barry Trachtenberg

POINTS TO REMEMBER

Onconephrology: An Evolving Field

POINTS TO REMEMBER

Herbal Nephropathy

EXCERPTA

Rolling the Dice on Red Yeast Rice

EDITORIALS

Letter to the Editor in Response to “Cardiac Autonomic Neuropathy in Diabetes Mellitus”